opnurasib
novartis
['jdq443', 'sclc', 'nsclc']
jdq443 is a kras g12c inhibitor with reasonable and expected efficacy and toxicity data. ability to combine safely with apd1 without hepatitis will be key differentiator amongst agents in this class #mediq23asco, #asco23 #nsclc 
We empower people at every level of the healthcare delivery system with the knowledge needed to continuously improve provider performance and patient outcomes.